TherapyX, Inc is Awarded Phase I Funding
Buffalo, NY-November 3, 2016 TherapyX is pleased to announce a new SBIR Phase I award to test its novel product, IL10NanoCap, a completely new nano encapsulated oral formulation of the key regulatory cytokine interleukin 10 (IL-10), in rodent models of inflammatory bowel disease. The NIH SBIR award, from the National Institute of Diabetes and Digestive and Kidney Diseases to Dr. Dominick L. Auci, MBA Ph.D., Vice President for Research and Development, aims at demonstrating proof of concept that orally administered IL10NanoCap can ameliorate established disease in several rodent models, to elucidate mechanism of action, and to provide preliminary pharmacotoxicology data.
“We are delighted with this new award ” said Dr. Dominick L. Auci, Vice President for Research and Development. “and excited about putting our new oral product, IL10NanoCap to the test in rodent models. We also continue the development of our two lead products, NGoXIMTM and TreXTAMTM towards clinical studies”
TherapyX, Inc. is developing a proprietary drug delivery system based on mild encapsulation of highly potent protein therapeutics into microparticles that preserves bioactivity, achieves controlled tissue specific release, reduced toxicity and shelf-stability. Its two lead products NGoXIMTM and TreXTAMTM are aimed at mucosal infections and inflammatory diseases, respectively. For more information on TherapyX contact the Company’s website at www.therapyxinc.com
CAUTIONARY STATEMENT: This press release may contain forward-looking statements concerning the potential and prospects of the Company’s drug discovery program and its drug candidates. Any statement describing a goal, expectation, intention or belief of the Company is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including the ability to complete preclinical and clinical trials successfully and within specified timelines, if at all; the ability to obtain regulatory approval; the Company’s future capital needs and ability to obtain additional funding; the ability of the Company to protect its intellectual property rights and to not infringe the intellectual property rights of others; the development of competitive products by other companies; and other risks detailed from time to time in the Company’s filings and press releases. Actual results may differ materially from those suggested in this press release.
Dominick Auci, 502-365-4522 Dauci@therapyXinc.com